Navigation Links
Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding
Date:12/5/2007

BOTHELL, Wash., Dec. 5 /PRNewswire-FirstCall/ -- Nastech Pharmaceutical Company Inc. (Nasdaq: NSTK) announced today that they have entered into a feasibility study with an undisclosed global leader in the production of plasma products, to develop an alternative dosage form of Factor IX protein which is currently administered by injection to control and prevent bleeding in patients with hemophilia B.

"We look forward to working with our new global partner to evaluate the feasibility of delivering Factor IX without an injection," stated Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech. "Patients with hemophilia B, a result of deficiency in the Factor IX protein, require a lifetime of frequent injections in order to manage their condition. An alternative to these injections would be welcomed by patients and their caregivers."

Factor IX is a protein produced naturally in the body that helps the blood to form clots. Hemophilia B, also known as Christmas disease, is a condition in which the body does not make enough Factor IX and is treated by injections of the protein. If a person does not have enough Factor IX and becomes injured, the blood will not form clots and they may bleed into and damage muscles and joints.

About Nastech

Nastech is a biopharmaceutical company developing innovative products based on proprietary molecular biology-based drug delivery technologies. Nastech and our collaboration partners are developing products for multiple therapeutic areas including osteoporosis, obesity, diabetes, autism, respiratory diseases and inflammatory conditions. Additional information about Nastech is available at http://www.nastech.com.

Nastech Forward Looking Statements

Statements made in this press release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Nastech to obtain additional funding; (ii) the ability of Nastech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) Nastech's and/or a partner's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) Nastech's and/or a partner's ability to obtain required governmental approvals; and (v) Nastech's and/or a partner's ability to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Nastech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Nastech

assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Contacts:

Nastech

Ed Bell

Director, Investor Relations

(425) 908-3639

ir@nastech.com

Russo Partners, LLC

David Schull (Media)

(212) 845-4271


'/>"/>
SOURCE Nastech Pharmaceutical Company Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Nastech to Host 2007 Analyst and Institutional Investor Day
2. Nastech to Release Third Quarter Financial Results and Host Webcast on Monday, October 29, 2007
3. Nastech Announces Third Quarter 2007 Financial Results
4. Nastech to Present at Acumen BioFin Rodman & Renshaw Healthcare Conference
5. Nastech to Present at BMO Capital Markets Focus on Healthcare Conference
6. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
7. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
8. Isis Enters Broad Collaboration With Ortho-McNeil, Inc. for the Discovery, Development and Commercialization of Antisense Drugs to Treat Metabolic Diseases
9. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
10. Cepheid Enters Agreement To Exclusively License HPV Portfolio Developed by Quantovir AB
11. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... ... Today, researchers can fast-track sample collection and analysis for ... or SNPs of interest) using one, easy-to-collect saliva sample. With the addition of ... and other relevant biomarkers can be extensively studied through a non-invasive sample type. ...
(Date:2/23/2017)... 2017 Aviva Systems Biology Corporation (ASB) ... of GenWay Biotech Incorporated, a protein solutions and ... offering for both the research and diagnostic markets. ... enhance capabilities for both entities. GenWay,s 18 years of ... nicely complement ASB,s objective to become a leading ...
(Date:2/22/2017)... , Feb. 22, 2017  Aratana Therapeutics, Inc. (NASDAQ: ... and commercialization of innovative biopharmaceutical products for companion animals, will ... at 8:30 a.m. ET to discuss financial results from the ... Interested participants and investors may access the ... ...
(Date:2/22/2017)... SAN DIEGO , Feb. 22, 2017  PrimeVax ... , will be presenting at the Annual Biocom Global ... on March 2, at 11:15 AM, at the Torrey ... are thankful to the organizers at Biocom who have ... this international symposium of biotechnology companies, investors, and clinical ...
Breaking Biology Technology:
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
(Date:2/21/2017)... LONDON , February 21, 2017 ... um 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr ... es einige Hindernisse zu überwinden gilt, um diese Prognose ... ... unter anderem die Mobilisierung der finanziellen Mittel für die ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
Breaking Biology News(10 mins):